TASSINARI, ELISA
 Distribuzione geografica
Continente #
EU - Europa 128
NA - Nord America 68
AS - Asia 19
AF - Africa 12
Totale 227
Nazione #
US - Stati Uniti d'America 66
IT - Italia 58
SE - Svezia 16
CH - Svizzera 13
CI - Costa d'Avorio 12
IE - Irlanda 12
JO - Giordania 12
BG - Bulgaria 11
FI - Finlandia 9
CN - Cina 3
FR - Francia 3
CA - Canada 2
HK - Hong Kong 2
IN - India 2
PL - Polonia 2
RU - Federazione Russa 2
AT - Austria 1
NL - Olanda 1
Totale 227
Città #
Bologna 15
Abidjan 12
Amman 12
Ashburn 12
Bern 12
Dublin 12
Sofia 11
Helsinki 7
Milan 7
Turin 5
Columbus 3
Paris 3
Rome 3
Telgate 3
Boardman 2
Gatineau 2
Genoa 2
Hong Kong 2
Hyderabad 2
Lappeenranta 2
Moscow 2
Warsaw 2
Amsterdam 1
Florence 1
Lugano 1
Ravenna 1
Seattle 1
Shijiazhuang 1
Trento 1
Vienna 1
Totale 141
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 28
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 26
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 25
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 21
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 20
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 19
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 17
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 14
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 14
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 11
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 10
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 9
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 8
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 8
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 7
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 7
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 6
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 4
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 2
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 2
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 1
Totale 268
Categoria #
all - tutte 1.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.287


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024131 10 18 13 8 14 29 4 15 11 5 4 0
Totale 268